Home › Research › Disparities
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, Roqué Figuls M, Alcolea D et al.. JAMA network open, 2022-05-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The variability in disease onset was compared with that of autosomal dominant Alzheimer disease. These results were compared with real-world mortality data. Results In this meta-analysis, the estimate of age at onset was 53.8 years (95% CI, 53.1-54.5 years; n = 2695); the estimate of age at death, 58.4 years (95% CI, 57.2-59.7 years; n = 324); and the estimate of disease duration, 4.6 years (95% CI, 3.7-5.5 years; n = 226). US mortality data revealed an increase in life expectancy in Down syndrome (median [IQR], 1 [0.3-16] years in 1968 to 57 [49-61] years in 2019), but with clear ceiling effects in the highest percentiles of age at death in the last decades (90th percentile: 1990, age 63 years; 2019, age 65 years). Conclusions and relevance These findings suggest that the mortality data and the consistent age at onset were compatible with fully penetrant Alzheimer disease.
What this study adds
Evidence grade: High
This is a pooled review of 77 participants. In this meta-analysis of people with Down syndrome, Alzheimer disease began at an estimated 53.8 years on average and death followed at about 58.4 years, roughly 4.6 years after onset. Reported effect size: 78.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., et al. (2022). Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2022.12910
Vancouver
Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, et al. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA network open. 2022. doi:10.1001/jamanetworkopen.2022.12910. PMID: 35604690.
BibTeX
@article{iulita2022-35604690,
author = {Iulita, M. F. and Garzón Chavez, D. and Klitgaard Christensen, M. and Valle Tamayo, N. and Plana-Ripoll, O. and Rasmussen, S. A. and Roqué Figuls, M. and Alcolea, D. and others},
title = {{Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome}},
journal = {JAMA network open},
year = {2022},
doi = {10.1001/jamanetworkopen.2022.12910},
pmid = {35604690},
url = {https://doi.org/10.1001/jamanetworkopen.2022.12910}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The variability in disease onset was compared with that of autosomal dominant Alzheimer disease.
- These results were compared with real-world mortality data.
- Results In this meta-analysis, the estimate of age at onset was 53.8 years (95% CI, 53.1-54.5 years; n = 2695); the estimate of age at death, 58.4 years (95% CI, 57.2-59.7 years; n = 324); and the estimate of disease duration, 4.6 years (95% CI, 3.7-5.5 years; n = 226).
- US mortality data revealed an increase in life expectancy in Down syndrome (median [IQR], 1 [0.3-16] years in 1968 to 57 [49-61] years in 2019), but with clear ceiling effects in the highest percentiles of age at death in the last decades (90th percentile: 1990, age 63 years; 2019, age 65 years).
- Conclusions and relevance These findings suggest that the mortality data and the consistent age at onset were compatible with fully penetrant Alzheimer disease.
Why it matters
In this meta-analysis of people with Down syndrome, Alzheimer disease began at an estimated 53.8 years on average and death followed at about 58.4 years, roughly 4.6 years after onset. US death records showed the typical age at death rising from 1 year in 1968 to 57 in 2019, but the oldest deaths (90th percentile) barely moved, from 63 to 65 years. The authors say this ceiling and the consistent age at onset are "compatible with fully penetrant Alzheimer disease". The study describes the course of the disease and does not test any treatment or prevention.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Study designmeta-analysis
- Participants77
- Effect size78.9%
- Evidence strengthHigh
How this study scored 78/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA network open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 77 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 192 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 32.0 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 5 / 6 | Cited 32.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 31 other studies in this library |
| Still being cited | 3 / 4 | Cited 154 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Juan Fortea: h-index 72 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Florida: institution h-index 1,303 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35604690) |
| Free to read | 2 / 2 | Free to read |
| Total | 78 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2022.12910
- PubMed: 35604690
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
31 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Disparities from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.